UNSPSC 51283943: Sulfacetamide sodium anhydrous

This classification denotes a sulfonamide anti-infective agent with the molecular formula C8H9N2O3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30760ZE777, chemically known as acetamide, n-((4-aminophenyl)sulfonyl)-, monosodium salt, but more generally known as sulfacetamide sodium anhydrous, which bears US NIH Compound Identifier 5320. European Medicines Agency schedules sulfacetamide sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10687MIG.

Most nations, for tariff purposes, schedule sulfacetamide sodium anhydrous under HS 29350090. SMILES: CC(=O)[N-]S(=O)(=O)C1CCC(CC1)N.[NA+].

UNSPSC 51283943 Sulfacetamide sodium anhydrous is a Commodity code that maps to pharmaceutical supply procurement, though the recent opportunities tagged under it show substantial scope mismatch—the code nominally describes a specific topical antibiotic compound, yet state and local solicitations are actually buying naloxone, first aid and emergency medical supplies, generic pharmaceuticals through cooperative channels, and pharmacy benefit program services. State and local governments acquire these products through health departments, fire-rescue divisions, and health and human services agencies for emergency response, community health support, and employee health benefit programs. The issuing bodies include county health systems (Seminole County, Florida), municipal fire departments (City of Tampa), state pharmacy benefit programs (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). When issuing bodies solicit under this code, they are typically sourcing consumable medical supplies with short shelf lives, bulk quantities for annual or multi-year terms, and products subject to FDA certification and cGMP compliance.

Geographic activity centers on Florida, Texas, and the Upper Midwest, with MMCAP's cooperative procurement extending across multiple states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (closed July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26-P-00145 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, designated as a sheltered market for Small Local Business Enterprises with an estimated contract value of $700,000; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and MMCAP's RFP S1070000015802 (due March 26, 2026) establishing multi-state contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026. The code sees limited current activity relative to its nominal scope—no solicitations directly match sulfacetamide sodium anhydrous procurement—suggesting the tagging may reflect a procurement system classification error rather than active demand for this specific pharmaceutical.